ReviewRheumatic diseases clinics of North America2014
Preclinical systemic lupus erythematosus.
Review in Rheumatic diseases clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.Lupus science & medicine · 2021Pooled it
- Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.BMC rheumatology · 2024Article
- Deciphering the different phases of preclinical inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Review
- Levels of anti-cyclic citrullinated peptide and antinuclear antibodies in Brazilian agricultural workers exposed to pesticides and fertilizers.The Science of the total environment · 2022Article
- Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.Nature reviews. Rheumatology · 2022Review
- A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.ACR open rheumatology · 2021Article
- Difference in thrombotic microangiopathy between concurrently and previously diagnosed systemic lupus erythematosus.Journal of the Chinese Medical Association : JCMA · 2020Article
- Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014.PloS one · 2020Article
- Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- PD-1 immunobiology in systemic lupus erythematosus.Journal of autoimmunity · 2019Review
- A Diet-Sensitive Commensal Lactobacillus Strain Mediates TLR7-Dependent Systemic Autoimmunity.Cell host & microbe · 2019Article
- Advances in the Research on Anticardiolipin Antibody.Journal of immunology research · 2019Review
- The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease.Arthritis research & therapy · 2018Article
- Anti-nuclear antibodies in patients with breast cancer.Clinical and experimental immunology · 2018Article
- Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Cell-bound complement activation products in SLE.Lupus science & medicine · 2017Review
- Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Preclinical lupus encompasses a spectrum from enhanced SLE risk without clinical symptoms to individuals with autoantibodies and some SLE clinical features without meeting ACR classification. Studies have identified antibody and serological biomarkers years before disease onset. Incomplete lupus and undifferentiated connective tissue disease may occur during preclinical disease periods, but only 10-20% of these individuals transition to SLE and many have a mild disease course. Further studies are warranted to characterize biomarkers of early disease, identify individuals in need of close monitoring or preventive interventions, and elucidate mechanisms of disease pathogenesis without confounding factors of immunosuppressive medications or organ damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.